Ocular Hypertension

The FDA approved Iyuzeh for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, according to a press release from Thea Pharma.

CHICAGO — In this video from Eyecelerator@AAO, SpyGlass Pharma CEO Patrick Mooney discusses the company’s drug delivery platform, which lowered IOP in patients with open-angle glaucoma or ocular hypertension.

Ocular hypertension is a risk factor for glaucoma, but in the absence of any glaucomatous damage it does not necessitate medical intervention.

Automated deep learning analysis of fundus photographs showed high diagnostic accuracy in determining primary open-angle glaucoma, with increased ability to detect glaucoma earlier than human readers.

Age, gender and central corneal thickness were among factors associated with elevated IOP in patients with primary open-angle glaucoma and ocular hypertension, according to a study published in British Journal of Ophthalmology.

The cumulative incidence of primary open-angle glaucoma after 20 years was almost 50% in patients with ocular hypertension, and the cumulative incidence of visual field loss was 25%, according to a study published in JAMA Ophthalmology.

The first patient in the Chinese portion of the Denali phase 3 clinical trial, investigating NCX 470 in patients with open-angle glaucoma or ocular hypertension, has been screened, according to a press release from Nicox.

Self-tonometry consistently evaluated diurnal IOP fluctuations in patients with ocular hypertension or open-angle glaucoma, according to a crossover clinical treatment trial in Optometry and Vision Science.

Netarsudil maintained IOP control and provided IOP-lowering efficacy when added to other treatments for patients with open-angle glaucoma or ocular hypertension, according to findings published in Current Medical Research and Opinion.

An interesting case was recently discussed among the optometrists and surgeons at Pacific Cataract and Laser Institute.